Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$92 Mln
Revenue (TTM)
$4 Mln
Net Profit (TTM)
$0 Mln
ROE
-4.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
11.9
Industry P/E
--
EV/EBITDA
-1.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4.2
Face value
--
Shares outstanding
28,599,300
CFO
$-188.48 Mln
EBITDA
$-182.40 Mln
Net Profit
$-277.60 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
| 53.8 | 6.4 | 7.6 | 29.3 | -42.8 | -43.6 | -- |
|
BSE Sensex*
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
| -4.8 | -61.0 | -85.2 | -9.2 | 6.2 | 63.0 | -70.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
3.7 | 91.5 | 3.8 | -58.2 | -1,349.4 | -584.1 | -- | 11.9 |
| 49.8 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.2 | 8,290.2 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 147.2 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.2 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 44.9 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 53.9 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 313.5 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 26.8 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 4.9 |
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing... DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Address: 15 Cushing, Irvine, CA, United States, 92618 Read more
President, CEO & Director
Mr. Joshua Riggs
President, CEO & Director
Mr. Joshua Riggs
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of OncoCyte Corp (OCX) stood at $ 70 Mln as on 31-Mar-25
The share price of OncoCyte Corp (OCX) is $3.66 (NASDAQ) as of 23-Jun-2025 09:30 EDT. OncoCyte Corp (OCX) has given a return of -42.83% in the last 3 years.
OncoCyte Corp (OCX) has a market capitalisation of $ 92 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of OncoCyte Corp (OCX) is 11.87 times as on 20-Jun-2025, a 325% premium to its peers’ median range of 2.79 times.
Since, TTM earnings of OncoCyte Corp (OCX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the OncoCyte Corp (OCX) and enter the required number of quantities and click on buy to purchase the shares of OncoCyte Corp (OCX).
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Address: 15 Cushing, Irvine, CA, United States, 92618
The CEO & director of Mr. Joshua Riggs. is OncoCyte Corp (OCX), and CFO & Sr. VP is Mr. Joshua Riggs.
There is no promoter pledging in OncoCyte Corp (OCX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| OncoCyte Corp (OCX) | Ratios |
|---|---|
|
Return on equity(%)
|
-584.12
|
|
Operating margin(%)
|
-1349.41
|
|
Net Margin(%)
|
-1514.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of OncoCyte Corp (OCX) was $0 Mln.
$0.50
(
